Obesity Treatment

Clinical trial of new antiobesity drug initiated

Published in Obesity and Diabetes Week, March 22nd, 2004

Arena Pharmaceuticals, Inc., (ARNA) announced that it has initiated a phase I clinical trial in the United Kingdom for APD356, its lead antiobesity compound.

This double-blind, placebo-controlled, single-dose, dose-escalation trial is planned to enroll 54 healthy, overweight volunteers. The study will evaluate the safety, tolerability and pharmacokinetic profile of APD356.

The single-dose protocol should be completed in the first half of this year and, if the results support further testing, Arena expects to begin a larger, multi-dose trial later this year to study the safety of multiple doses of APD356 and to examine weight loss in a double-blind,...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Obesity and Diabetes Week

Source: Obesity and Diabetes Week (2004-03-22)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry